Virax Biolabs Reports Positive Pilot Data for ViraxImmune™ in Long COVID and PAIS

On May 26, 2026, Virax Biolabs Group Limited reported positive early pilot performance data for ViraxImmune™, its blood-based diagnostic test under development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and other post-acute infection syndromes (PAIS). The pilot dataset demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and a 92% positive predictive value (PPV). To date, the test has been evaluated in over 120 subjects in an ongoing UK clinical study. Based on these encouraging metrics, the company is preparing for a larger clinical validation analysis involving samples from 300 additional participants. Virax intends to pursue an initial U.S. market-entry strategy via a Laboratory Developed Test (LDT) route, followed by broader in vitro diagnostic (IVD) development. The company estimates a significant market opportunity with up to 21 million adults in the U.S. living with PAIS conditions. Analysis for the next validation phase is expected to begin in Q4 2026.